Movano Health reports Q2 net loss $7.3M; Evie Ring launch planned before Black Friday 2023

Corvex, Inc.

2023-Q2 EPS reported -$0.36

Net loss $7.3M ($0.17 per share) vs $6.9M loss ($0.21 per share) in Q2 2022; no revenue.
Cash $14.5M at June 30, 2023, up from $10.8M at year-end 2022; raised $9.2M in public offering.
FDA 510(k) for Evie Ring pulse oximeter under full review; launch expected before Black Friday 2023.
Over 600,000 website visitors YTD and 100,000 sign-ups for Evie Ring updates.
Beta partners include global athletic apparel, major health insurer, and remote patient monitoring company.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Corvex, Inc. reported three months ending June 30, 2023 results: net income $7.3 million, EPS $(0.17) per basic and diluted share.

Period: three months ending June 30, 2023
Net income: $7.3 million
EPS: $(0.17) per basic and diluted share
Result: reported results

Exact text from the filing

Movano Health reported a net loss of $7.3 million and a loss of $(0.17) per basic and diluted share, in the second quarter of 2023

View on SEC.gov

Browse all earnings releases →

Corvex, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-067081

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.